Yüklüyor......
Phase I Study of Pasireotide (SOM 230) and Everolimus (RAD001) in Advanced Neuroendocrine Tumors
Octreotide and everolimus have demonstrated efficacy in neuroendocrine tumors. Pasireotide is a somatostatin analog with binding affinity to a broader range of somatostatin receptor subtypes than octreotide. We performed a phase I study to evaluate the safety and feasibility of combining pasireotide...
Kaydedildi:
| Yayımlandı: | Endocr Relat Cancer |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2012
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4469068/ https://ncbi.nlm.nih.gov/pubmed/22736724 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-11-0382 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|